首页> 外文OA文献 >The dynamic landscape of BRCA1 reversion mutations from indel to SNV in a patient with ovarian cancer treated with PARP-inhibitors and immunotherapy

【2h】

The dynamic landscape of BRCA1 reversion mutations from indel to SNV in a patient with ovarian cancer treated with PARP-inhibitors and immunotherapy

机译：用PARP-抑制剂和免疫疗法治疗卵巢癌患者SNV的BRCA1逆转突变的动态景观

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Saya L. Jacob; Lesli A. Kiedrowski; Young K. Chae;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer [J] . van der Biessen Diane A. J., Gietema Jourik A., de Jonge Maja J. A., Investigational new drugs. . 2018,第5期

机译：通过BRCA1 / 2突变和高级浆液卵巢，输卵管或原发性腹膜癌，对PARP抑制剂ABT-767进行PARP抑制剂ABT-767的研究
2. Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer [J] . Christie Elizabeth L., Fereday Sian, Doig Ken, Journal of Clinical Oncology . 2017,第12期

机译：从高级浆液癌患者循环肿瘤DNA检测到BRCA1 / 2种系突变的恢复
3. Prevalence of BRCA1/2 mutations in sporadic breast/ovarian cancer patients and identification of a novel de novo BRCA1 mutation in a patient diagnosed with late onset breast and ovarian cancer: Implications for genetic testing [J] . DeLeeneerK., CoeneI., CrombezB., Breast cancer research and treatment. . 2012,第1期

机译：散发性乳腺癌/卵巢癌患者中BRCA1 / 2突变的患病率和新诊断的新型BRCA1突变在诊断为晚期乳腺癌和卵巢癌的患者中的鉴定：基因检测的意义
4. An Integrated Microfluidic Platform for Detecting BRCA1/BRCA2 Gene Mutation and Risk Assessment of Ovarian Cancer [C] . Yu-Hung Cheng, Chih-Hung Wang, Keng-Fu Hsu, International Conference on Solid-State Sensors, Actuators and Microsystems . 2021

机译：一种用于检测BRCA1 / BRCA2基因突变和卵巢癌风险评估的集成微流体平台
5. Dolo?anje Mutacij v Genih BRCA1/2 Iz citolo?kega Materiala Pri Raku jaj?nikov, Jajcevodov in Primarnem Peritonealnem Seroznem Karcinomu =BRCA1/2 mutation testing from cytological samples in patients with ovarian, tubal and primary peritoneal serous cancer [D] . Gornjec, Andreja. 2020

机译：从自我癌症中确定基因Krca1 / 2中的突变吗？
6. The dynamic landscape of BRCA1 reversion mutations from indel to SNV in a patient with ovarian cancer treated with PARP-inhibitors and immunotherapy [O] . Saya L. Jacob, Lesli A. Kiedrowski, Young K. Chae 2020

机译：PARP抑制剂和免疫疗法治疗卵巢癌患者BRCA1突变从indel到SNV的动态变化
7. Treatment-emergent neuroendocrine prostate cancer with a germline BRCA2 mutation: identification of a candidate reversion mutation associated with platinum/PARP-inhibitor resistance [O] . Deep Pandya, Myra Shah, Fuat Kaplan, 2021

机译：治疗新芽的神经内分泌前列腺前列腺癌与种系BRCA2突变：鉴定铂/ PARP抑制剂抗性相关的候选回归突变
8. Cancer Risks Associated With Inherited Mutations in Ovarian Cancer Susceptibility Genes Beyond BRCA1 and BRCA2. [R] . Swisher, E. 2017

机译：与BRCa1和BRCa2之外的卵巢癌易感基因的遗传突变相关的癌症风险。

The dynamic landscape of BRCA1 reversion mutations from indel to SNV in a patient with ovarian cancer treated with PARP-inhibitors and immunotherapy

著录项

引文网络

相似文献

相关主题

期刊订阅